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found that titrating inhaled corticosteroids using a combination of FeNO and sputum eosinophils reduced
exacerbation rates and asthma symptoms compared to a conventional strategy, without additional increases
in inhaled corticosteroid doses.
In conclusion, serial FeNO measurements may identify airway inflammation within close temporal proximity
to changes in conventional biomarkers of eosinophilic disease such as sputum eosinophil count, with the
added value of being of point-of-care. Further prospective trials are required to assess if this approach can
successfully predict exacerbations or be used to titrate therapy in adults with asthma.
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Quality standards for the management of
bronchiectasis in Italy: a national audit
To the Editor:
Although historically considered a neglected disease, bronchiectasis has become a disease of renewed
interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare
systems [1–3]. In 2010, the British Thoracic Society (BTS) published guidelines on the management of
bronchiectasis in adults, along with specific quality standards [4, 5]. To date, these represent the only
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quality standards available in Europe. These have been tested over a number of years in the UK with
progressive improvements in the standard of care [6]. No national guidelines are available in Italy and no
indications on which guideline should be followed have been given by the Italian Society of Respiratory
Medicine (SIP). There are limited published data on the quality of bronchiectasis care in Europe outside of
the UK. The BTS standards have not been tested in continental Europe or in Italy, where information on
characteristics and management of bronchiectasis patients are lacking.
A national audit was conducted by the SIP on adult patients with bronchiectasis who attended secondary
care clinics in 32 hospitals across Italy in 2014 and 2015. An invitation to participate in the audit was sent
to the chiefs of pulmonary departments in Italy, as well as members of the SIP. They were asked to
complete an electronic case report form (CRF) for each patient enrolled, concordant with the CRF used in
the 2012 UK audit [6]. A total of 1361 records were submitted from 32 institutions across the country.
The majority of the patients were female (n=719, 53%) and the median (interquartile range (IQR)) age
was 70 (59–77) years. Pseudomonas aeruginosa was isolated at least once during the previous year in 20%
of the patients, enteric Gram-negative organisms in 7.8% and methicillin-resistant Staphylococcus aureus
(MRSA) in 2.9%. A total of 158 (12%) patients had a chronic infection with P. aeruginosa, defined as the
presence of this pathogen in at least two consecutive sputum samples collected in stable state over 1-year
period [7].
43% of the patients had two or more exacerbations per year, while 18% had three or more exacerbations
per year, with a median (IQR) of 2 (2–3) exacerbations per year. 49% had been hospitalised at least once
in the previous year for lower respiratory tract infections (LRTI). The median (IQR) number of antibiotic
courses for LRTI in the previous year was 2 (2–3), with 40% of the study population receiving three or
more antibiotic courses in the previous year. Specifically, 36% of them received at least one course of
intravenous antibiotics because of an exacerbation during the previous year.
The prevalence of chronic infection with P. aeruginosa was lower than the prevalence of patients with two
to three or more exacerbations or hospitalisations per year, and some explanations might be suggested for
that. On one hand, we can speculate that frequent exacerbators are also those with either an intermittent
infection with P. aeruginosa or chronic infections with other bacteria, as recently reported [8], and that
microbiology is just one of several bronchiectasis features responsible for bad outcomes [7]. On the other
hand, hospitalisations for LRTI in bronchiectasis patients might be also due to factors not strictly related
to bronchiectasis and infection, such as the presence of decompensated comorbidities or failure of oral
antibiotic therapy [9]. The rate of P. aeruginosa isolation (20%) in the present audit is very similar to the
reported prevalence of P. aeruginosa in 21 cohorts recently included in a meta-analysis where the mean
frequency of isolation was 21.4% [10]. We suspect that the frequency of P. aeruginosa may be
underestimated due to a lack of regular sputum sampling in Italy (see later).
A total of 119 (9%) patients were on long-term antibiotic treatment, either orally or by inhalation. 7.8%
had received long-term oral antibiotics for >28 days and among them, 74 were taking azithromycin, 11
levofloxacin, nine ciprofloxacin, three moxifloxacin, three trimethoprim/sulfamethoxazole, two
clarithromycin and one amoxicillin/clavulanate. Only 1.1% of the patients had received long-term inhaled/
nebulised antibiotics for >28 days. Among them, 10 were on tobramycin, three on colomycin and two on
gentamicin. Four patients were on both oral and inhaled/nebulised long-term antibiotic treatment.
The BTS quality standard for the management of patients with bronchiectasis evaluated in the present
audit comprises 10 statements. The adherence to these standards is depicted in figure 1.
In order to make a diagnosis of bronchiectasis, the first quality statement recommends a computed
tomography (CT) of the chest using 1-mm slices. In this SIP audit, 93% of the patients had a CT scan,
although only 46% had a high-resolution CT scan. Bronchiectasis was diagnosed by chest radiography in 5%
and by bronchography in 1% of the rest of the population, while 1% had a clinical diagnosis alone. The second
statement recommends that patients should be investigated for allergic bronchopulmonary aspergillosis
(ABPA), common variable immunodeficiency (CVID) and cystic fibrosis (CF), the last of these if indicated, as
these are specific and treatable causes of bronchiectasis [11]. In the SIP audit, only 435 (32%) patients were
tested for at least one of the above: 17% of the patients had been investigated for ABPA, 22% for CVID and
5.5% for CF. Furthermore, 9.3% of patients were tested for IgG subclasses, 4.7% for HIV, 8.2% for
α1-antitripsin deficiency, 18% for autoantibodies and 2.6% for either saccharin test or electronic microscopy
for ciliary dysfunction. Finally, no tests to investigate the aetiology of bronchiectasis were performed in 59% of
the patients. The third and fourth statements require that people with bronchiectasis have sputum bacterial
culture when clinically stable recorded at least once each year and at the start of an exacerbation before
initiating antibiotics. 27% had at least one sputum sent for bacterial culture in stable state during the previous
year and almost 50% at the beginning of an exacerbation. The fifth statement proposes that people with
bronchiectasis are taught appropriate airway clearance techniques by a specialist respiratory physiotherapist
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and advised of the frequency and duration with which these should be carried out. In the SIP audit, only 44%
of the patients were taught chest clearance techniques by a specialist respiratory physiotherapist. The sixth
statement proposes that people with bronchiectasis and breathlessness affecting their activities of daily living
should attend pulmonary rehabilitation, in order to improve their exercise capacity and health status. 49% of
Italian patients had breathlessness and among those, 49% attended a pulmonary rehabilitation programme.
The seventh statement requires that there should be provision of nebulised prophylactic antibiotics for suitable
patients supervised by a respiratory specialist. All 20 patients receiving long-term nebulised antibiotics for
>1 month were supervised by respiratory physicians using off-label treatment. The eighth statement is that
people with bronchiectasis should have an individualised written self-management plan in order to manage
their condition and to recognise, respond to and reduce the occurrence of exacerbations. In the SIP audit, 56%
of the patients shared an individualised written self-management plan. The ninth standard is that people with
bronchiectasis who meet the criteria for continuing secondary care should be managed by a multidisciplinary
team led by a respiratory physician. These are patients with chronic P. aeruginosa, mycobacteria or MRSA,
three or more exacerbations per year, receiving long-term antibiotic treatment, bronchiectasis associated with
rheumatoid arthritis, immune deficiency, inflammatory bowel disease, primary ciliary dyskinesia or ABPA,
and advanced disease, and/or considering lung transplantation. Among the 665 patients who met these
criteria, the majority (94%) was seen by respiratory physicians at a secondary care level (20% were seen every
2 months, 32% every 4 months, 36% were seen 6-monthly and 12% once a year) and 6% by general
practitioners. Furthermore, only four out of the 32 study centres participating in the audit have a specific
bronchiectasis clinic taking care of 221 (16%) patients in total. The development of tertiary-care bronchiectasis
clinics should be a priority at national level in order to offer the most severe patients a better and
multidisciplinary management of their disease. The final statement concerns services for people with
bronchiectasis, which should include provision of home i.v. antibiotic treatment for exacerbations in selected
patients. In the audit, only 2.3% were offered domiciliary i.v. antibiotics. Only one out of 32 centres was able
to offer a domiciliary treatment with i.v. antibiotics for an exacerbation.
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FIGURE 1 Summary of the quality statements for bronchiectasis in adults and percentage adherence in the
Italian Society of Respiratory Medicine (SIP) Audit. #: people with a clinical diagnosis of bronchiectasis have the
diagnosis confirmed by chest computed tomography (CT) scan (using 1 mm slices). ¶: people with bronchiectasis
to be investigated for allergic bronchopulmonary aspergillosis, common variable immunodeficiency and cystic
fibrosis (the last of these, if indicated), as these are specific treatable causes. +: people with bronchiectasis have
sputum bacteriology culture when clinically stable recorded at least once each year. §: sputum is sent for
bacterial culture at the start of an exacerbation before starting antibiotics; empirical antibiotic treatment to start
as soon as feasible and not await the sputum culture results. ƒ: people with bronchiectasis are taught
appropriate airway clearance techniques by a specialist respiratory physiotherapist and advised of the frequency
and duration with which these should be carried out. ##: people with bronchiectasis to attend pulmonary
rehabilitation if they have breathlessness affecting their activities of daily living. ¶¶: services for people with
bronchiectasis to include provision of nebulised prophylactic antibiotic therapy (ABT) for suitable patients
supervised by a respiratory specialist. ++: people with bronchiectasis to have an individualised, written
self-management plan. §§: people with bronchiectasis who meet the criteria for continuing secondary care to be
managed by a multidisciplinary team led by a respiratory physician. ƒƒ: services for people with bronchiectasis to
include provision of home intravenous ABT for exacerbations in selected patients.
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The majority of the BTS recommendations for the management of bronchiectasis in adults were not met
in Italy, with six out of 10 being reached in <50% of the patients. A lower percentage of patients
undergoing high-resolution CT scan and standard testing for bronchiectasis aetiology is reported in the
present SIP audit in comparison to the 2012 UK audit [6]. Five more areas require particular attention,
including: monitoring sputum bacteriology; promoting airway clearance taught by a specialist respiratory
physiotherapist and pulmonary rehabilitation in selected patients; and developing services to allow
domiciliary intravenous antibiotic treatment [12]. Possible reasons for low adherence to the quality
standards include the absence of Italian and European guidelines, and lack of awareness of the disease and
of the evidence base to support recommendations. Following the results of this audit, we suggest, on one
hand, increasing educational activities on bronchiectasis at a national level according to the Harmonising
Education in Respiratory Medicine for European Specialists (HERMES) curriculum and promoting access
to the HERMES diploma, and on the other hand, to develop and subsequently implement national or
European guidelines. Results of this intervention might lead to a better care of our patients, as the third
UK audit demonstrated in comparison to the previous ones [6]. One tool to monitor the implementation
of standard operating procedures in Italy will be the SIP national registry of adult patients with
bronchiectasis that has been recently developed and linked to the EMBARC European registry [13].
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